| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
|
J Clin Oncol
|
2005
|
4.03
|
|
2
|
Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment.
|
Lung Cancer
|
2008
|
2.37
|
|
3
|
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.
|
Breast Cancer Res
|
2011
|
1.69
|
|
4
|
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.
|
BMC Cancer
|
2007
|
1.68
|
|
5
|
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens.
|
Invest New Drugs
|
2010
|
1.62
|
|
6
|
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
|
Clin Cancer Res
|
2006
|
1.53
|
|
7
|
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer.
|
Int J Cancer
|
2005
|
1.52
|
|
8
|
Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer.
|
Ann Surg Oncol
|
2009
|
1.41
|
|
9
|
The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.
|
Oncogene
|
2004
|
1.38
|
|
10
|
Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells.
|
Oncogene
|
2003
|
1.38
|
|
11
|
The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
|
BMC Cancer
|
2008
|
1.38
|
|
12
|
Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer.
|
Breast Cancer Res
|
2012
|
1.33
|
|
13
|
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.
|
Mol Cancer Ther
|
2009
|
1.32
|
|
14
|
Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.
|
PLoS One
|
2009
|
1.30
|
|
15
|
Aggressiveness of cancer-care near the end-of-life in Korea.
|
Jpn J Clin Oncol
|
2008
|
1.29
|
|
16
|
ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
|
Lung Cancer
|
2007
|
1.29
|
|
17
|
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
|
Lung Cancer
|
2008
|
1.28
|
|
18
|
Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type.
|
Blood
|
2005
|
1.24
|
|
19
|
The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
|
Cancer Lett
|
2008
|
1.23
|
|
20
|
Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
|
Lung Cancer
|
2007
|
1.23
|
|
21
|
HIF-2alpha enhances beta-catenin/TCF-driven transcription by interacting with beta-catenin.
|
Cancer Res
|
2010
|
1.20
|
|
22
|
Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression.
|
Cancer Res
|
2006
|
1.20
|
|
23
|
Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1alpha in gastric cancer cells.
|
Clin Cancer Res
|
2003
|
1.20
|
|
24
|
Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer.
|
BMC Gastroenterol
|
2011
|
1.20
|
|
25
|
Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin.
|
Int J Oncol
|
2008
|
1.19
|
|
26
|
Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells.
|
Mol Cancer Ther
|
2006
|
1.18
|
|
27
|
KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.
|
Mol Carcinog
|
2010
|
1.18
|
|
28
|
DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma.
|
Biochem Biophys Res Commun
|
2007
|
1.16
|
|
29
|
The role of PET/CT in detection of gastric cancer recurrence.
|
BMC Cancer
|
2009
|
1.16
|
|
30
|
Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
|
Clin Cancer Res
|
2004
|
1.14
|
|
31
|
Clinicopathologic features and clinical outcomes of gastric cancer that initially presents with disseminated intravascular coagulation: a retrospective study.
|
J Gastroenterol Hepatol
|
2010
|
1.14
|
|
32
|
AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity.
|
Oncogene
|
2004
|
1.14
|
|
33
|
Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study.
|
Jpn J Cancer Res
|
2002
|
1.14
|
|
34
|
Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.
|
Jpn J Clin Oncol
|
2011
|
1.13
|
|
35
|
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
|
BMC Cancer
|
2007
|
1.13
|
|
36
|
CPR or DNR? End-of-life decision in Korean cancer patients: a single center's experience.
|
Support Care Cancer
|
2005
|
1.12
|
|
37
|
A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor-1alpha gene.
|
Biochem J
|
2002
|
1.12
|
|
38
|
Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone.
|
Jpn J Clin Oncol
|
2003
|
1.12
|
|
39
|
Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
|
Cancer Res
|
2008
|
1.11
|
|
40
|
Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment.
|
J Neurooncol
|
2011
|
1.11
|
|
41
|
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.
|
BMC Cancer
|
2008
|
1.11
|
|
42
|
Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
|
Mol Cancer Ther
|
2011
|
1.10
|
|
43
|
Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing.
|
PLoS One
|
2013
|
1.10
|
|
44
|
Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
|
Cancer Chemother Pharmacol
|
2011
|
1.09
|
|
45
|
Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
|
Breast Cancer Res Treat
|
2008
|
1.09
|
|
46
|
ALU and LINE-1 hypomethylations in multistep gastric carcinogenesis and their prognostic implications.
|
Int J Cancer
|
2012
|
1.07
|
|
47
|
Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy--result of chemotherapy in NK/T-cell lymphoma.
|
Acta Oncol
|
2003
|
1.06
|
|
48
|
Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma.
|
Lung Cancer
|
2008
|
1.06
|
|
49
|
Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins.
|
Cancer Sci
|
2011
|
1.05
|
|
50
|
The endogenous ratio of Smad2 and Smad3 influences the cytostatic function of Smad3.
|
Mol Biol Cell
|
2005
|
1.04
|
|
51
|
Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.
|
Cancer Chemother Pharmacol
|
2007
|
1.04
|
|
52
|
Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.
|
Cancer Chemother Pharmacol
|
2007
|
1.04
|
|
53
|
Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy.
|
J Mol Med (Berl)
|
2007
|
1.03
|
|
54
|
Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
|
BMC Cancer
|
2008
|
1.03
|
|
55
|
RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib.
|
Mol Cancer Ther
|
2013
|
1.02
|
|
56
|
Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
|
J Thorac Oncol
|
2010
|
1.01
|
|
57
|
Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy.
|
BMC Cancer
|
2010
|
1.01
|
|
58
|
Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase.
|
J Mol Med (Berl)
|
2007
|
1.01
|
|
59
|
NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.
|
Int J Oncol
|
2011
|
1.00
|
|
60
|
Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody.
|
PLoS One
|
2012
|
1.00
|
|
61
|
Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status.
|
Virchows Arch
|
2011
|
0.99
|
|
62
|
Transforming growth factor-beta 1 induces apoptosis through Fas ligand-independent activation of the Fas death pathway in human gastric SNU-620 carcinoma cells.
|
Mol Biol Cell
|
2003
|
0.99
|
|
63
|
Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.
|
Cancer Chemother Pharmacol
|
2012
|
0.99
|
|
64
|
Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.
|
Mol Cancer Ther
|
2008
|
0.98
|
|
65
|
A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
|
Oncology
|
2009
|
0.98
|
|
66
|
Aberrant methylation of integrin alpha4 gene in human gastric cancer cells.
|
Oncogene
|
2004
|
0.98
|
|
67
|
Zinc-fingers and homeoboxes 1 (ZHX1) binds DNA methyltransferase (DNMT) 3B to enhance DNMT3B-mediated transcriptional repression.
|
Biochem Biophys Res Commun
|
2007
|
0.97
|
|
68
|
Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells.
|
Mol Cells
|
2010
|
0.97
|
|
69
|
Gene silencing of TSPYL5 mediated by aberrant promoter methylation in gastric cancers.
|
Lab Invest
|
2007
|
0.97
|
|
70
|
Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.
|
Lung Cancer
|
2006
|
0.97
|
|
71
|
Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
|
Int J Cancer
|
2012
|
0.97
|
|
72
|
The signaling network of transforming growth factor beta1, protein kinase Cdelta, and integrin underlies the spreading and invasiveness of gastric carcinoma cells.
|
Mol Cell Biol
|
2005
|
0.96
|
|
73
|
Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors.
|
Biochem Biophys Res Commun
|
2008
|
0.96
|
|
74
|
KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
|
Ann Surg Oncol
|
2014
|
0.96
|
|
75
|
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
|
J Hepatol
|
2013
|
0.96
|
|
76
|
Role of adjuvant chemoradiotherapy for ampulla of Vater cancer.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.96
|
|
77
|
A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer.
|
Oncol Rep
|
2004
|
0.95
|
|
78
|
OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells.
|
Cancer Lett
|
2013
|
0.95
|
|
79
|
Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy.
|
J Cancer Res Clin Oncol
|
2011
|
0.95
|
|
80
|
Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers.
|
Lab Invest
|
2012
|
0.95
|
|
81
|
Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
|
Mol Cancer Ther
|
2012
|
0.94
|
|
82
|
Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer.
|
Jpn J Clin Oncol
|
2008
|
0.93
|
|
83
|
Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience.
|
Am J Clin Oncol
|
2012
|
0.93
|
|
84
|
Ataxia-telangiectasia-mutated protein expression with microsatellite instability in gastric cancer as prognostic marker.
|
Int J Cancer
|
2013
|
0.93
|
|
85
|
The value of preoperative staging chest computed tomography to detect asymptomatic lung and liver metastasis in patients with primary breast carcinoma.
|
Breast Cancer Res Treat
|
2011
|
0.93
|
|
86
|
Cell adhesion status-dependent histone acetylation is regulated through intracellular contractility-related signaling activities.
|
J Biol Chem
|
2005
|
0.93
|
|
87
|
RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase.
|
Cancer Lett
|
2010
|
0.93
|
|
88
|
Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer.
|
Oncol Rep
|
2005
|
0.93
|
|
89
|
Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.
|
Jpn J Clin Oncol
|
2006
|
0.93
|
|
90
|
Gefitinib resistance of cancer cells correlated with TM4SF5-mediated epithelial-mesenchymal transition.
|
Biochim Biophys Acta
|
2011
|
0.92
|
|
91
|
High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.
|
Breast Cancer Res Treat
|
2010
|
0.92
|
|
92
|
Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less.
|
BMC Cancer
|
2010
|
0.91
|
|
93
|
Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma.
|
Cancer
|
2004
|
0.91
|
|
94
|
First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma.
|
Leuk Lymphoma
|
2006
|
0.91
|
|
95
|
Metaplastic breast carcinoma: clinicopathologic features and prognostic value of triple negativity.
|
Jpn J Clin Oncol
|
2009
|
0.90
|
|
96
|
Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy.
|
BMC Cancer
|
2011
|
0.90
|
|
97
|
Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy.
|
J Korean Med Sci
|
2009
|
0.90
|
|
98
|
Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
|
Am J Clin Oncol
|
2011
|
0.90
|
|
99
|
TGF-beta1-mediated activations of c-Src and Rac1 modulate levels of cyclins and p27(Kip1) CDK inhibitor in hepatoma cells replated on fibronectin.
|
Biochim Biophys Acta
|
2005
|
0.90
|
|
100
|
Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation.
|
J Gastroenterol Hepatol
|
2008
|
0.90
|
|
101
|
Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer.
|
Cancer Chemother Pharmacol
|
2013
|
0.90
|
|
102
|
Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.
|
Dis Colon Rectum
|
2012
|
0.89
|
|
103
|
CpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological features.
|
Virchows Arch
|
2010
|
0.89
|
|
104
|
The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen.
|
Anticancer Res
|
2012
|
0.89
|
|
105
|
DNA methylation changes in ex-adenoma carcinoma of the large intestine.
|
Virchows Arch
|
2010
|
0.89
|
|
106
|
Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6.
|
Cancer Sci
|
2009
|
0.89
|
|
107
|
Proteomic analysis reveals that CD147/EMMPRIN confers chemoresistance in cancer stem cell-like cells.
|
Proteomics
|
2013
|
0.89
|
|
108
|
Identification of DNA methylation changes associated with human gastric cancer.
|
BMC Med Genomics
|
2011
|
0.89
|
|
109
|
Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
|
Pharmacogenet Genomics
|
2007
|
0.88
|
|
110
|
RNA editing in RHOQ promotes invasion potential in colorectal cancer.
|
J Exp Med
|
2014
|
0.88
|
|
111
|
Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.
|
Diagn Mol Pathol
|
2011
|
0.87
|
|
112
|
Mad1 mediates hypoxia-induced doxorubicin resistance in colon cancer cells by inhibiting mitochondrial function.
|
Free Radic Biol Med
|
2013
|
0.87
|
|
113
|
Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung).
|
Am J Clin Oncol
|
2012
|
0.87
|
|
114
|
Regulation of DeltaNp63alpha by tumor necrosis factor-alpha in epithelial homeostasis.
|
FEBS J
|
2007
|
0.87
|
|
115
|
Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study.
|
BMC Cancer
|
2009
|
0.86
|
|
116
|
ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.
|
Oncology
|
2012
|
0.86
|
|
117
|
Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage.
|
Cancer
|
2003
|
0.86
|
|
118
|
Cyclooxygenase-2 inhibits novel ginseng metabolite-mediated apoptosis.
|
Cancer Res
|
2005
|
0.86
|
|
119
|
Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer.
|
Jpn J Clin Oncol
|
2005
|
0.86
|
|
120
|
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
|
Gastric Cancer
|
2012
|
0.85
|
|
121
|
A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma.
|
Cancer
|
2004
|
0.85
|
|
122
|
Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection.
|
BMC Cancer
|
2011
|
0.85
|
|
123
|
Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.
|
Oncology
|
2012
|
0.85
|
|
124
|
Whole-body distribution and radiation dosimetry of (68)Ga-NOTA-RGD, a positron emission tomography agent for angiogenesis imaging.
|
Cancer Biother Radiopharm
|
2011
|
0.85
|
|
125
|
Mixed-type gastric cancer and its association with high-frequency CpG island hypermethylation.
|
Virchows Arch
|
2010
|
0.85
|
|
126
|
TGF-beta1 (transforming growth factor-beta1)-mediated adhesion of gastric carcinoma cells involves a decrease in Ras/ERKs (extracellular-signal-regulated kinases) cascade activity dependent on c-Src activity.
|
Biochem J
|
2004
|
0.84
|
|
127
|
ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.
|
Cancer Sci
|
2014
|
0.84
|
|
128
|
Metastasis-associated protein S100A4 and p53 predict relapse in curatively resected stage III and IV (M0) gastric cancer.
|
Cancer Invest
|
2008
|
0.84
|
|
129
|
Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer.
|
Cancer Lett
|
2012
|
0.84
|
|
130
|
Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma.
|
Clin Transl Oncol
|
2012
|
0.84
|
|
131
|
Prognostic value of p53 and bcl-2 expression in patients treated with breast conservative therapy.
|
J Korean Med Sci
|
2010
|
0.84
|
|
132
|
Gadoxetic acid-enhanced MRI and diffusion-weighted imaging for the detection of colorectal liver metastases after neoadjuvant chemotherapy.
|
Eur Radiol
|
2015
|
0.84
|
|
133
|
A-kinase anchoring protein 12 regulates the completion of cytokinesis.
|
Biochem Biophys Res Commun
|
2008
|
0.83
|
|
134
|
Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
|
Jpn J Clin Oncol
|
2008
|
0.83
|
|
135
|
Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.
|
Cancer Lett
|
2011
|
0.83
|
|
136
|
Nomogram prediction of survival and recurrence in patients with extrahepatic bile duct cancer undergoing curative resection followed by adjuvant chemoradiation therapy.
|
Int J Radiat Oncol Biol Phys
|
2013
|
0.83
|
|
137
|
Smad2 mediates Erk1/2 activation by TGF-beta1 in suspended, but not in adherent, gastric carcinoma cells.
|
Int J Oncol
|
2004
|
0.83
|
|
138
|
Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line.
|
Exp Mol Med
|
2013
|
0.82
|
|
139
|
DNA methyltransferase 3B mutant in ICF syndrome interacts non-covalently with SUMO-1.
|
J Mol Med (Berl)
|
2008
|
0.82
|
|
140
|
Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
|
J Med Chem
|
2003
|
0.82
|
|
141
|
Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer.
|
Lung Cancer
|
2003
|
0.82
|
|
142
|
Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
|
Breast Cancer
|
2012
|
0.82
|
|
143
|
UBR2 of the N-end rule pathway is required for chromosome stability via histone ubiquitylation in spermatocytes and somatic cells.
|
PLoS One
|
2012
|
0.82
|
|
144
|
DNA methyltransferase 3-like affects promoter methylation of thymine DNA glycosylase independently of DNMT1 and DNMT3B in cancer cells.
|
Int J Oncol
|
2010
|
0.81
|
|
145
|
High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy.
|
Clin Cancer Res
|
2006
|
0.81
|
|
146
|
Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis.
|
Cancer Chemother Pharmacol
|
2010
|
0.81
|
|
147
|
Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1alpha synthesis in HT-29 colon cancer cells.
|
Biochem Biophys Res Commun
|
2010
|
0.81
|
|
148
|
Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer.
|
J Korean Med Sci
|
2005
|
0.81
|
|
149
|
DNA methyltransferase 3B acts as a co-repressor of the human polycomb protein hPc2 to repress fibroblast growth factor receptor 3 transcription.
|
Int J Biochem Cell Biol
|
2008
|
0.81
|
|
150
|
Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme.
|
J Neurooncol
|
2002
|
0.81
|
|
151
|
A novel ginseng saponin metabolite induces apoptosis and down-regulates fibroblast growth factor receptor 3 in myeloma cells.
|
Int J Oncol
|
2003
|
0.81
|
|
152
|
Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy.
|
Invest New Drugs
|
2012
|
0.81
|
|
153
|
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
|
Lung Cancer
|
2009
|
0.81
|
|
154
|
Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells.
|
Anticancer Res
|
2006
|
0.80
|
|
155
|
Age <40Years is an independent prognostic factor predicting inferior overall survival in patients treated with breast conservative therapy.
|
Breast J
|
2010
|
0.80
|
|
156
|
Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer.
|
Invest New Drugs
|
2011
|
0.80
|
|
157
|
Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy.
|
Breast Cancer
|
2012
|
0.80
|
|
158
|
Increasing nodal ratio is a poor prognostic factor for survival in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study.
|
Jpn J Clin Oncol
|
2010
|
0.80
|
|
159
|
Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer.
|
Jpn J Clin Oncol
|
2005
|
0.80
|
|
160
|
Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer.
|
Ann Surg Oncol
|
2013
|
0.79
|
|
161
|
17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy.
|
Exp Ther Med
|
2011
|
0.79
|
|
162
|
Is duodenal invasion a relevant prognosticator in patients undergoing adjuvant chemoradiotherapy for distal common bile duct cancer?
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.79
|
|
163
|
Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy.
|
Cancer
|
2010
|
0.79
|
|
164
|
Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer.
|
Cancer Chemother Pharmacol
|
2013
|
0.79
|
|
165
|
Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer.
|
Tumori
|
2011
|
0.79
|
|
166
|
Open-label, randomized comparison of the efficacy of intravenous dolasetron mesylate and ondansetron in the prevention of acute and delayed cisplatin-induced emesis in cancer patients.
|
Cancer Res Treat
|
2004
|
0.79
|
|
167
|
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
|
Oncol Rep
|
2005
|
0.78
|
|
168
|
Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy.
|
Support Care Cancer
|
2011
|
0.78
|
|
169
|
Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells.
|
Anticancer Drugs
|
2012
|
0.78
|
|
170
|
The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines.
|
Invest New Drugs
|
2011
|
0.78
|
|
171
|
Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer.
|
Cancer Res Treat
|
2008
|
0.78
|
|
172
|
Role of adjuvant chemoradiotherapy for duodenal cancer: a single center experience.
|
Am J Clin Oncol
|
2012
|
0.78
|
|
173
|
Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma.
|
Anticancer Res
|
2010
|
0.78
|
|
174
|
Primary systemic anaplastic large cell lymphoma in a single Korean institution: clinical characteristics and treatment outcome.
|
J Korean Med Sci
|
2006
|
0.78
|
|
175
|
Does adjuvant radiotherapy suppress liver regeneration after partial hepatectomy?
|
Int J Radiat Oncol Biol Phys
|
2008
|
0.78
|
|
176
|
Cytotoxic effects of pemetrexed in gastric cancer cells.
|
Cancer Sci
|
2005
|
0.78
|
|
177
|
Establishment and characterization of six human lung cancer cell lines: EGFR, p53 gene mutations and expressions of drug sensitivity genes.
|
Cell Oncol (Dordr)
|
2011
|
0.78
|
|
178
|
CD24 expression predicts distant metastasis in extrahepatic bile duct cancer.
|
World J Gastroenterol
|
2013
|
0.78
|
|
179
|
Prognostic implication of (18)F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study.
|
Cancer Chemother Pharmacol
|
2010
|
0.78
|
|
180
|
A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
|
Am J Clin Oncol
|
2014
|
0.78
|
|
181
|
The influence of the treatment response on the impact of resection margin status after preoperative chemoradiotherapy in locally advanced rectal cancer.
|
BMC Cancer
|
2013
|
0.77
|
|
182
|
Distant metastasis risk stratification for patients undergoing curative resection followed by adjuvant chemoradiation for extrahepatic bile duct cancer.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.77
|
|
183
|
HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
|
Cancer Chemother Pharmacol
|
2013
|
0.77
|
|
184
|
Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.
|
Cancer Chemother Pharmacol
|
2011
|
0.77
|
|
185
|
A Phase II study of 5-fluorouracil and cisplatin systemic chemotherapy for inoperable hepatocellular carcinoma with α fetoprotein as a predictive and prognostic marker.
|
Mol Med Rep
|
2011
|
0.77
|
|
186
|
Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement.
|
Ann Hematol
|
2009
|
0.77
|
|
187
|
Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells.
|
Cancer Lett
|
2011
|
0.77
|
|
188
|
Body mass index is not associated with treatment outcomes of breast cancer patients receiving neoadjuvant chemotherapy: korean data.
|
J Breast Cancer
|
2012
|
0.76
|
|
189
|
Functional assessment staging (FAST) in Korean patients with Alzheimer's disease.
|
J Alzheimers Dis
|
2010
|
0.76
|
|
190
|
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
|
PLoS One
|
2012
|
0.76
|
|
191
|
Gefitinib for refractory advanced non-small-cell lung cancer.
|
Lancet
|
2006
|
0.75
|
|
192
|
Efficacy of exemestane in korean patients with metastatic breast cancer after failure of nonsteroidal aromatase inhibitors.
|
J Breast Cancer
|
2013
|
0.75
|
|
193
|
A New Isolated Mediastinal Lymph Node or Small Pulmonary Nodule Arising during Breast Cancer Surveillance Following Curative Surgery: Clinical Factors That Differentiate Malignant from Benign Lesions.
|
Cancer Res Treat
|
2014
|
0.75
|
|
194
|
Hypoxia-inducible factor 1alpha- mediated resistance to phenolic anticancer.
|
Chemotherapy
|
2004
|
0.75
|
|
195
|
The synergism between Belotecan and cisplatin in gastric cancer.
|
Cancer Res Treat
|
2006
|
0.75
|
|
196
|
Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.
|
Cancer Chemother Pharmacol
|
2013
|
0.75
|
|
197
|
Negative impact of heat exposure on cosmesis after conservative treatment for breast cancer.
|
Tumori
|
2008
|
0.75
|
|
198
|
Induction chemotherapy followed by radiotherapy in the treatment of anal cancer.
|
Oncol Rep
|
2002
|
0.75
|
|
199
|
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
|
Cancer Chemother Pharmacol
|
2014
|
0.75
|
|
200
|
A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer.
|
Cancer Chemother Pharmacol
|
2015
|
0.75
|
|
201
|
Phosphorylated Akt Expression as a Favorable Prognostic Factor for Patients Undergoing Curative Resection and Adjuvant Chemoradiotherapy for Proximal Extrahepatic Bile Duct Cancer.
|
Am J Clin Oncol
|
2017
|
0.75
|
|
202
|
Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer.
|
Jpn J Clin Oncol
|
2005
|
0.75
|
|
203
|
Prognostic Significance of Nodal Ratio in Patients Undergoing Adjuvant Chemoradiotherapy After Curative Resection for Ampullary Cancer.
|
Am J Clin Oncol
|
2016
|
0.75
|
|
204
|
The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use.
|
Jpn J Clin Oncol
|
2012
|
0.75
|
|
205
|
Prognostic factors affecting the outcome of salvage radiotherapy for isolated locoregional recurrence after mastectomy.
|
Am J Clin Oncol
|
2010
|
0.75
|
|
206
|
Overexpression of A-kinase anchoring protein 12A activates sterol regulatory element binding protein-2 and enhances cholesterol efflux in hepatic cells.
|
Int J Biochem Cell Biol
|
2008
|
0.75
|
|
207
|
VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib.
|
Diagn Mol Pathol
|
2011
|
0.75
|